A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests. The new vaccine strategy, described in a paper on November 23 in Science Advances, is based on the HIV envelope protein, Env. This complex, shape-shifting molecule has been notoriously difficult to produce in vaccines in a way that induces useful immunity to HIV. However, the Scripps Research scientists found a simple, elegant method for stabilizing Env proteins in the desired shape even for diverse strains of HIV. Mounted on virus-like particles to mimic a whole virus, the stabilized Env proteins elicited robust anti-HIV antibody responses in mice and rabbits. Candidate vaccines based on this strategy are now being tested in monkeys.
- Published
- 27 November 2018
- From
-
Scripps Research Institute
Money is just the obvious obstacle. A few diseases, like H.I.V., so far have outwitted both the immune system and scientists.
- Published
- 22 November 2018
- From
-
New York Times
HIV prevention research funding continued to decline in 2017 for the fifth consecutive year, driven largely by a five-year low in US public sector funding, according to a report released today at the HIV Research for Prevention (HIVR4P 2018) conference in Madrid, Spain.
- Published
- 26 October 2018
- From
-
HIV Prevention R&D Working Group
Johnson & Johnson has already advanced a “mosaic” HIV vaccine candidate into efficacy testing in five southern African countries, but this week the company unveiled initial results from an early-stage study comparing tetravalent and trivalent candidates in its program.
- Published
- 24 October 2018
- From
-
Fierce Pharma
The Global HIV Vaccine Enterprise, hosted by the International AIDS Society (IAS), has launched a five-year strategy to accelerate the development of an effective vaccine to prevent HIV infection. The new Global HIV Vaccine Enterprise Strategic Plan (2018-2023) was unveiled today at the opening of HIV Research for Prevention (HIVR4P 2018), the world’s only scientific conference dedicated exclusively to biomedical HIV prevention, in Madrid, Spain.
- Published
- 23 October 2018
- From
-
International AIDS Society
Duke researchers have recently discovered why some people can produce antibodies capable of fighting HIV, and the answer might lie in one special protein.
- Published
- 18 October 2018
- From
-
Duke Chronicle
The finding advances efforts to develop a vaccine that elicits protective HIV antibodies.
- Published
- 01 October 2018
- From
- Science Daily
Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers have now shown that the genome of the HI virus is a decisive factor in determining which antibodies are formed.
- Published
- 11 September 2018
- From
- Science Daily
Unless the $3 billion spent annually on research triples, the world may not be able to invent vaccines or rapid cures for many ills of the poor.
- Published
- 10 September 2018
- From
- New York Times
The Campbell Foundation’s latest grant funds research into the RV144 trial in Thailand, which showed 31 percent protection against HIV.
- Published
- 29 August 2018
- From
-
Poz
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...